arrow
S

Shahrukh K. Hashmi

Mayo Clinic
H指数:54
被引数:1.0万

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Reduced-Dose Post-Transplant Cyclophosphamide as Graft-Versus-Host Disease Prophylaxis in Matched Donor Allogeneic Stem Cell Transplantation: A Systematic Review of Efficacy and Toxicity

减低剂量移植后环磷酰胺作为匹配供体异基因干细胞移植中移植物抗宿主病预防措施:一项关于疗效和毒性的系统综述

2026-06-300
PRE
Real-World Outcomes of Infections Following Tisagenlecleucel in Patients with B-Cell ALL: A CIBMTR Analysis

tisagenleucel治疗后B-Cell ALL患者感染的实时世界结局:一项CIBMTR分析

2025-08-050
OAAI
Chimeric antigen receptor T-cell therapy for high-grade B-cell lymphoma NOS

嵌合抗原受体T细胞疗法治疗高级别B细胞淋巴瘤NOS

2025-07-220
PRE
Correction: Non-cryopreserved autologous peripheral blood stem cell transplantation for multiple myeloma and lymphoma in countries with limited resources: practice considerations from the Worldwide Network for Blood and Marrow Transplantation

更正:在资源有限国家中,使用非冷冻保存的自体外周血干细胞移植治疗多发性骨髓瘤和淋巴瘤:来自世界骨髓移植联盟的实践考量

2025-06-300
PRE
Delayed T-cell recovery after hematopoietic cell transplantation is associated with decreased overall survival in adults

造血细胞移植后T细胞恢复延迟与成人总生存率降低相关

2025-04-210
OA
Haploidentical, matched-related, and matched-unrelated hematopoietic cell transplant for acute leukemias in the early years of haploidentical transplant implementation in a developing country with a large unrelated donor registry

半相合、匹配亲属和匹配非亲属造血细胞移植在半相合移植实施早期,在一个拥有大型非亲属供者登记库的发展中国家的急性白血病中的应用

2025-04-150
OA
Impact of Race and Ethnicity on Outcomes After Umbilical Cord Blood Transplantation

种族和民族对脐血移植后结局的影响

2024-10-010
PRE
Severity of Chronic Graft-versus-Host Disease and Late Effects Following Allogeneic Hematopoietic Cell Transplantation for Adults with Hematologic Malignancy

成人血液系统恶性肿瘤患者异基因造血干细胞移植后慢性移植物抗宿主病的严重程度和迟发效应

2024-01-013
OAAI
Allogeneic hematopoietic cell transplantation for blastic plasmacytoid dendritic cell neoplasm: a CIBMTR analysis
2023-11-177
OAAI
Racial and Socioeconomic Disparities in Long-Term Outcomes in ≥1 Year Allogeneic Hematopoietic Cell Transplantation Survivors: A CIBMTR Analysis

≥ 1年异基因造血干细胞移植幸存者长期结果的种族和社会经济差异: CIBMTR分析

2023-11-016
PRE
The Transplantation Ecosystem: A New Concept to Improve Access and Outcomes for Older Allogeneic Hematopoietic Cell Transplantation Patients

移植生态系统: 改善老年异基因造血细胞移植患者的获得和结果的新概念

2023-10-017
OAAI
A real-world international observational study of mogamulizumab in adult patients with mycosis fungoides and Sezary syndrome (PROSPER study NCT05455931)
2023-09-010
PRE
Impact of Donor Age on Allogeneic Hematopoietic Cell Transplantation Outcomes in Older Adults with Acute Myeloid Leukemia

供者年龄对老年急性髓系白血病异基因造血干细胞移植结局的影响

2023-09-0112
OAAI
Real-world experience with ponatinib therapy in chronic phase chronic myeloid leukemia: impact of depth of response on survival and prior exposure to nilotinib on arterial occlusive events
2023-08-113
OAAI